<table>
<thead>
<tr>
<th>Title</th>
<th>Processive phosphorylation of ERK MAP kinase in mammalian cells.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Aoki, Kazuhiro; Yamada, Masashi; Kunida, Katsuyuki; Yasuda, Shuhei; Matsuda, Michiyuki</td>
</tr>
<tr>
<td>Citation</td>
<td>Proceedings of the National Academy of Sciences of the United States of America (2011)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2011-07-18</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/143060">http://hdl.handle.net/2433/143060</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>author</td>
</tr>
</tbody>
</table>

Kyoto University
Title page

Classification: Biological Sciences, Biochemistry, Cell Biology

Title

Processive phosphorylation of ERK MAP kinase in mammalian cells

Kazuhiro Aoki, a,b,1,* Masashi Yamada, c,l Katsuyuki Kunida, c Shuhei Yasuda, a and Michiyuki Matsuda a,c

a Laboratory of Bioimaging and Cell Signaling, Graduate School of Biostudies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan,
b PREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
c Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
1 These authors contributed equally to this work.

* Correspondence: k-aoki@lif.kyoto-u.ac.jp

Keywords: ERK, simulation, processive model, distributive model
Abstract

The mitogen-activated protein (MAP) kinase pathway is comprised of a three-tiered kinase cascade. The distributive kinetic mechanism of two-site MAP kinase phosphorylation inherently generates a non-linear switch-like response. However, a linear graded response of MAP kinase has also been observed in mammalian cells, and its molecular mechanism remains unclear. To dissect these input-output behaviors, we quantitatively measured the kinetic parameters involved in the MEK-ERK MAP kinase signaling module in HeLa cells. Using a numerical analysis based on experimentally determined parameters, we predicted in silico and validated in vivo that ERK is processively phosphorylated in HeLa cells. Finally, we identified molecular crowding as a critical factor that converts distributive phosphorylation into processive phosphorylation. We proposed the term quasi-processive phosphorylation to describe this mode of ERK phosphorylation that is operated under the physiological condition of molecular crowding. The generality of this phenomenon may provide a new paradigm for a diverse set of biochemical reactions including multiple posttranslational modifications.
Introduction

Mitogen-activated protein (MAP) kinase cascades are evolutionarily conserved signaling pathways that are involved in the control of physiological and pathological cellular processes including cell proliferation, survival, differentiation, apoptosis, and tumorigenesis (1-4). Each MAP kinase pathway contains a three-tiered kinase cascade consisting of a MAP kinase kinase kinase, a MAP kinase kinase, and the MAP kinase, which are sequentially activated in this order. MAP kinases, which are activated by dual phosphorylation of conserved threonine and tyrosine residues within the activation loop, phosphorylate their targets on serine or threonine residues (1, 3, 5). Five distinct groups of MAP kinases have been characterized in mammals. Among them, the most studied is the Raf/MEK/ERK MAP kinase cascade (hereafter called the ERK MAP kinase cascade), which is activated by mitogenic ligands such as growth factors, cytokines, and phorbol esters.

Ferrell and coworkers found that in Xenopus oocytes the ERK MAP kinase pathway responds to increasing levels of progesterone in an all-or-none or “switch-like” manner, in which individual cells in the population exhibit either “on” or “off” status (6, 7). This property of ERK MAP kinase system befits to determine all-or-none irreversible responses including cell-cycle progression, neuronal differentiation, and T cell selection (6-10). The switch-like responses can arise from both positive feedback via protein synthesis and dual phosphorylation steps of the MAP kinase, which is called the “distributive phosphorylation model” (11-15) (Fig. 1A). The distributive model of ERK phosphorylation results in an increase in the cooperativity of this system, and consequently contributes to a switch-like input-output response.
In different cellular contexts, however, the ERK MAP kinase cascade exhibits “graded” response, in which all cells in the population uniformly gain their signal output proportionally in response to the level of input stimulus. This input-output response is observed in the pheromone-stimulated \textit{S. cerevisiae} (16-18) and growth factor stimulated-HeLa cells and fibroblasts (19, 20). These graded responses can suit the physiological property of signaling, including the reversibility and the activation by different inputs with a wide range of threshold doses (18). However, MAP kinase cascades should inherently induce the switch-like response behavior due to the three-tiered enzyme cascade. To answer this question, it has been theoretically proposed that scaffold proteins might convert the switch-like response into the graded response (21). Here, the scaffold protein holds MAP kinase kinase and MAP kinase, thereby inducing dual phosphorylation at a single collision, which is called the “processive phosphorylation model” (11, 21-25). However, it is not known whether the scaffold proteins in mammals contribute to the processive phosphorylation of MAP kinase (10). Hence, the mechanism by which MAP kinase activity adopts a graded response remains unclear in mammalian cells.

In this study, we demonstrate for the first time that ERK is phosphorylated in a processive manner by employing quantitative simulation model of the ERK MAP kinase cascade. Furthermore, a condition that mimics physiological molecular crowding has been shown to convert the mode of ERK phosphorylation from distributive to processive. Under this condition, MEK and ERK do not form a stable complex as proposed in the processive phosphorylation model. Therefore, we propose that ERK is phosphorylated in a “quasi-processive” manner under the physiological condition of molecular crowding.
Results

Kinetic parameters that determine the dynamics of the MEK-ERK signaling module

Our goal is to comprehend the systems behavior of the MEK-ERK signaling module. To this end, we attempted to determine most, if not all, of the kinetic parameters required for the kinetic simulation model, using HeLa cells as a model system. The model requires four classes of parameters: protein concentrations, association/dissociation rates, nuclear import/export rates, and phosphorylation/dephosphorylation rates. We experimentally determined approximately 30 parameters (SI Appendix, Fig. S1-7 and Tables S1 and S2). Notably, this study focused on the phosphorylation kinetics of the MEK-ERK module in the early phase of the signaling event. Thus, we neglected the role of ERK-induced gene expression of negative regulators such as dual specificity phosphatases (DUSPs), which shape the dynamics of intracellular signaling starting from 30 min after ligand addition (26).

In vitro phosphorylation rates of ERK measured by Phos-tag gel electrophoresis

All parameters used in this study are determined in living HeLa cells except for the phosphorylation rates of ERK, which was determined as follows. MEK activates ERK by phosphorylating two critical amino acid residues within the activation loop, threonine and tyrosine; therefore, we quantified four phospho-isoforms of ERK, non-phosphorylated ERK (np-ERK), tyrosine mono-phosphorylated ERK (pY-ERK), threonine mono-phosphorylated ERK (pT-ERK), and bis-phosphorylated ERK (pTpY-ERK) by Phos-tag western blotting (27). Phos-tag is a phosphorylated amino acid chelator. Because the electrophoretic mobility of phosphorylated proteins is significantly reduced in separation gels containing Phos-tag, the
fractions of non-phosphorylated and phosphorylated proteins can be visualized quantitatively. Notably, the effect of Phos-tag on the electrophoretic mobility varies among phospho-proteins, demanding a preliminary experiment of the identification of each phospho-protein by immunoblotting with specific antibodies (SI Appendix, Fig. S4). We found that the order of electrophoretic mobility in the Phos-tag gel was, from the slowest to fastest, pY-ERK, pTpY-ERK, pT-ERK, and np-ERK. This order was also confirmed with phosphatase inhibitors. Treatment with the phospho-tyrosine phosphatase inhibitor bpV, and the phospho-serine/threonine phosphatase inhibitor Calyculin A, increased the intensity of the pY-ERK and pT-ERK bands, respectively (SI Appendix, Fig. S6).

The rates of ERK phosphorylation by MEK were first determined in vitro using a kinase-dead mutant of ERK2 (ERK2-KR) and constitutively active mutant of MEK1 (MEK1-SDSE). As previously demonstrated (11), pY-ERK was initially accumulated, followed by pTpY-ERK (Fig. 1B and 1C). pT-ERK could not be detected under this condition. Importantly, the amount of the intermediate product, pY-ERK, exceeded that of the enzyme, MEK1-SDSE (3.0 x 10^{-7} M in Fig. 1C), indicating that ERK was phosphorylated by a manner consistent with the distributive phosphorylation model in vitro (11). In this way, we obtained the first and second reaction rates with linear assumption (k_{cat}/K_m) of 3.9 x 10^{4} [M/sec] and 2.1 x 10^{4} [M/sec], respectively (SI Appendix, Fig. S5 and Table S2). The reason why pT-ERK was not detected may be because the first step of the reactions from np-ERK to pT-ERK is markedly slower than the second step from pT-ERK to pTpY-ERK in vitro. Therefore, the phosphorylation reaction rate (k_{cat}/K_m) from pT-ERK to pTpY-ERK was examined in vitro using pT-ERK as a substrate, and was found to be 2.0 x 10^{4} [M/sec] (SI Appendix, Table S2). Thus, pT-ERK production from np-ERK could be ignored at least in the phosphorylation reactions (SI Appendix, Fig. S5G).
Validation of the distributive phosphorylation model

Based on these parameters determined experimentally (SI Appendix, Tables S1 and S2), we built a distributive phosphorylation model of the MEK-ERK signaling module (Fig. 2A and SI Appendix, Fig. S8A), and numerically solved the ERK phosphorylation (Fig. 2B and 2C). The input signal, i.e., the turnover rate of MEK phosphorylation by cRaf, was initially set to 1.0 x 10^6 [M/sec] to reproduce the experimental data, and was varied with a broad range (SI Appendix, Fig. S9). Upon stimulation in silico, pY-ERK was steeply increased, followed by a gradual increase in pTpY-ERK and pT-ERK (Fig. 2B). pY-ERK was predominant over pTpY-ERK in low input strength, and vice versa for high input strength at 10 min after stimulation (Fig. 2C). These data were consistent with the distributive phosphorylation model demonstrated in vitro (Fig. 1) and in Xenopus oocytes (6, 11).

We next examined whether the phosphorylation of ERK2 in HeLa cells follows the distributive model. Against the prediction in silico, the increase in pY-ERK2 did not precede to, but rather accompanied the increase in pTpY-ERK2 upon EGF stimulation (Fig. 2D and 2E). Furthermore, pY-ERK2 increased in a dose-dependent manner as the EGF input increased (Fig. 2F and 2G), but did not increase in a bell-shaped manner as predicted in silico (Fig. 2C). Of note, we could not detect the endogenous pT-ERK2 quantitatively due to the low abundance and to the signals of co-migrating pY-ERK1.

Prediction of a processive phosphorylation model in silico

Because we determined all parameters in the cells except for the phosphorylation reaction rates, which were obtained in vitro, we speculated that the discrepancy between the experimental and
*in silico* data of the MEK-induced ERK phosphorylation might have arisen from parameters related to the phosphorylation rates of ERK. Hence, we built a processive model by changing one reaction pathway of the distributive model (Fig. 3A and SI Appendix, Fig. S8B, Tables S1 and S2). Here, activated MEK does not dissociate from pY-ERK but processively phosphorylates threonine of pY-ERK to generate pTpY-ERK. Therefore, this model contains two species of pY-ERK, i.e. pY-ERK in complex with MEK and pY-ERK generated by the dephosphorylation of pTpY-ERK.

With this processive model, the experimental observation (Fig. 2D-2G) was reproduced successfully (Fig. 3B, 3C and SI Appendix, Fig. S9). Namely, the increase in pY-ERK paralleled the increase in pTpY-ERK both in the time course analysis and the input-output response analysis. These results implied that ERK is processively phosphorylated by MEK.

**Experimental validation of the processive model 1: pY-ERK dynamics**

By employing computer-assisted kinetic simulation, we designed an experimental condition that distinguishes between the distributive model and the processive model. When cells are stimulated in the presence of phosphatase inhibitors, pY-ERK will be increased in the distributive model (Fig. 4A, green lines, and SI Appendix, Fig. S10A) and decreased in the processive model (Fig. 4B, green lines, and SI Appendix, Fig. S10B). This is because pY-ERK is generated primarily as the intermediate phosphorylation product in the distributive model, whereas in the processive model pY-ERK is produced by the dephosphorylation of pTpY-ERK. For the execution of the designed experiment, HeLa cells were stimulated with EGF in the absence or presence of inhibitors for tyrosine- and serine/threonine-phosphatase, bpV and Calyculin A, respectively. As expected in the processive model, phosphatase inhibitors substantially reduced
the accumulation of pY-ERK, arguing for the processive phosphorylation model (Fig. 4C and 4D).

**Experimental validation of the processive model 2: Input-output response**

Previous studies supported the distributive phosphorylation model primarily because it explains the non-linear switch-like response of MAP kinase upon stimulation. Therefore, to understand the contribution of the MEK-ERK signaling module to the switch-like response of ERK to EGF, we examined the input-output behavior of ERK phosphorylation in our experimental conditions. We quantified the amount of pTpY-ERK1/2 in individual cells by immuno-staining with anti-pTpY-ERK1/2 antibody. As reported previously in HeLa cells and fibroblasts stimulated with EGF and TPA, respectively (19, 20), this approach could provide quantitative relationship between the input signal and output response (Fig. 5A and 5B). The Hill coefficient obtained by this method was 2.09 (Fig. 5B). Next, we confirmed this observation by western blotting, which also demonstrated a mild non-linear cooperativity, having 1.91 Hill coefficient (Fig. 5C). However, when we examined the correlation of the fraction of active MEK with the fraction of pTpY-ERK, we observed almost linear input-output response of ERK, having 1.18 Hill coefficient (Fig. 5D). Importantly, this Hill coefficient value determined experimentally was nearly identical to the Hill coefficient calculated at 1.19 by the processive model (Fig. 5F), but significantly smaller than the Hill coefficient calculated at 1.61 by the distributive model (Fig. 5E). Notably, the Hill coefficients might be slightly overestimated because they were calculated at the time point before reaching plateau. Nevertheless, these results strongly supported the processive model, which should exhibit linear input-output response.
**Numerical validation of the processive model**

To examine which of the distributive and processive models is the plausible mechanism to account for the observed data (Fig. 2E and Fig. 4D), we calculated residual sum of squares (RSS) values, Akaike information criterion (AIC) values, and Hill coefficients for both models after parameter fitting (28) (Fig. S11). This in silico validation was performed under three conditions of different numbers of variables. Condition 1: all phosphorylation rates were multiplied by a common constant value, which was optimized to fit the experimental data. Condition 2: the phosphorylation rates were individually fitted to the experimental data. Condition 3: in addition to the phosphorylation rates, the dephosphorylation rates were also fitted individually to the experimental data. In all conditions, experimentally-determined parameters were used as the initial values for the fitting. In Conditions 1 and 2, the processive model was more plausible than the distributive model because the AIC of the former model was smaller than the AIC of the latter model. Although both distributive and processive models exhibited the lowest RSS in Condition 3, the AIC values were higher than those in the other conditions, which indicated over-fitting in Condition 3. Importantly, the Hill coefficients calculated by the processive model were closer to the experimental value than the Hill coefficients calculated by the distributive model (Fig. 5F). Taken together, these analyses strongly argued that ERK is processively phosphorylated by MEK in HeLa cells.

**Molecular crowding as a determinant for processive phosphorylation**

What kind of factor(s) is a critical determinant for changing the distributive nature of ERK phosphorylation into the processive one in the cells? A critical difference between the environment *in vitro* and that within cells is the effect of molecular crowding (29, 30). To
evaluate the effect of molecular crowding, we examined whether or not ERK is phosphorylated in a processive manner in diluted cytoplasmic cell extract. Similarly to the results of *in vitro* ERK phosphorylation, ERK is phosphorylated in a distributive manner in the cytoplasmic extract, which was manifested by the initial accumulation of pY-ERK (SI Appendix, Fig. S12). Conversely, we mimicked the physiological molecular crowding by adding 15% (wt/vol) polyethylene glycol (PEG) to *in vitro* kinase reaction solution as a crowder (31) (Fig. 6A and 6B). The addition of PEG reduced the production rate of pY-ERK without changing the net production rate of pTpY-ERK, indicating an increase in the “processivity” of ERK phosphorylation (Fig. 6C and 6D). Lastly, we built a partial processive model by combining the distributive and processive models and fitted it to the experimental data (Fig. 6E). For this we introduced two additional parameters: Processivity, p, as the probability of pTpY-ERK production in the processive manner, and crowding factor, c, as the effect of the crowder or viscosity on the net reaction rates. By the fitting we found that the presence of 15% PEG increased in the processivity of ERK phosphorylation of 47%, and decreased the reaction rates to 27% by viscosity (Fig. 6C and 6D). Of note, the amount of pY-ERK at the zenith exceeded the net amount of MEK (Fig. 6D, dashed line), indicating that pY-ERK was not accumulated due to the sequestration by MEK binding. Thus, the molecular crowding within the cells could convert the distributive phosphorylation in vitro to the processive phosphorylation as seen in the cells.
Discussion

In this study, we have demonstrated for the first time that the amino acid residues in the activation loop of ERK, threonine and tyrosine, are processively phosphorylated in HeLa cells, and have identified molecular crowding as one possible factor in determining whether the mode of phosphorylation will be distributive or processive. The term “processive phosphorylation” is used to describe reactions in which the substrate-enzyme complex is stable during the first and second phosphorylation reactions, which is not the case for the phosphorylation of ERK (Fig. 6D). We therefore proposed the term “quasi-processive phosphorylation” to describe two sequential phosphorylation reactions that are controlled by molecular crowding (Fig. 6F). In this model, MEK first phosphorylates ERK at the tyrosine residue and dissociates from the product, pY-ERK. Under the physiological conditions within cells, the diffusions of both MEK and pY-ERK are considerably restricted by the molecular crowding effect; therefore, MEK rebinds to and phosphorylates pY-ERK with high probability. Consequently, MEK phosphorylates ERK in a processive manner. Another MAP kinase, p38, also exhibited typical hallmarks of the processive phosphorylation (SI Appendix, Fig. S13), indicating the generality of the quasi-processive phosphorylation of MAP kinase within cells. In contrast to the phosphorylation step, this quasi-processive phosphorylation model could not be applicable to the dephosphorylation step of pTpY-ERK, because the premise of quasi-processive phosphorylation is sequential reactions operated by the identical enzyme. The dephosphorylation reactions of phospho-threonine and phospho-tyrosine were mediated probably by different classes of phosphatase at least in our experimental conditions (SI Appendix, Fig. S6).

The quasi-processive phosphorylation is critically different from the previously proposed processive phosphorylation model, in which scaffold proteins anchor MEK and ERK in order to cause sequential phosphorylation reactions by a single collision (21). The scaffold proteins are
known to regulate assembly of two or more components of signaling pathways in many signaling cascades (21-25). As far as we have examined, however, none of the scaffold proteins for MEK and ERK contributed significantly to cause the processivity of ERK phosphorylation (SI Appendix, Fig. S14), consistent with the previous study on KSR (10). Therefore, at this moment, we failed to obtain any evidence that scaffold proteins cause processive phosphorylation in mammalian cells. Importantly, Takahashi and Pryciak have concluded that sole expression of Ste5 scaffold did not induce linear response of MAP kinase phosphorylation in yeast, and instead the recruitment of the scaffold to the plasma membrane resulted in linear response of MAP kinase phosphorylation (18). This seems to fit very well with our findings, in that the effect of Ste5 could be due to molecular crowding or confinement, rather than scaffolding per se. Recently, Takahashi et al, demonstrated by particle simulation that rapid rebinding of enzyme molecules to the substrate after modification of the first site can turn a distributive model into a processive model (32). They have predicted that molecular crowding will make enzyme-substrate rebindings more likely due to subdiffusion, strongly providing the theoretical basis of our findings.

It has been suggested that the high cooperativity of Xenopus oocytes in reaction to progesterone stimulation is at least partly accomplished by the distributive phosphorylation of ERK (6, 7). Some degree of molecular crowding probably exists in Xenopus oocytes, indicating an important point of disagreement between these previous studies and our present findings. However, it should be noted that the phosphorylation dynamics of ERK phospho-isoforms has only been investigated in vitro, and has never been investigated experimentally in Xenopus oocytes or cells. Therefore, it is possible that ERK is processively phosphorylated in Xenopus oocytes as in HeLa cells. There may exist non-linear reactions in the signaling pathway upstream
of MEK, e.g., receptor phosphorylation or Mos activation, in *Xenopus* oocytes. Actually, the input-output relationship between EGF concentration and pTpY-ERK demonstrated higher cooperativity; namely, the Hill coefficient was almost two (Fig. 5A-C). In contrast, the Hill coefficient for active MEK and pTpY-ERK phosphorylation was approximately one, implying the presence of a non-linear reaction(s) in the signaling cascade upstream of MEK. Consistent with this assumption, it has been reported that EGFR phosphorylation responded in a highly amplified and switch-like manner by coupling EGFR activation and PTP inhibition (33).

As has been described in this study, the discrepancy between the data acquired from the cells and the data predicted by the kinetic simulation model led us to the finding that ERK is processively phosphorylated within cells. Therefore, our results underscore the importance of simulation models based on experimentally determined kinetic parameters. Another important message from this study is that, in some cases, the physiological condition of molecular crowding significantly affected the mode of phosphorylation. Recent proteomic data demonstrates that proteins in a eukaryotic cell harbor multiple phosphorylation sites, each of which regulates different functions of their proteins (24). Therefore, molecular crowding, which is ubiquitous in biological systems, introduces additional complexity in their regulation. Thus, the finding that molecular crowding changes the mode of successive reactions to a processive type provides a new paradigm for a diverse set of biochemical reactions.
Materials and Methods

Plasmids, cells, reagents and antibodies

The plasmids used here were constructed according to the standard methods. Cells, reagents and antibodies are detailed in SI Appendix.

Purification of recombinant proteins, cytoplasm extract and in vitro kinase assay

Details of purification of recombinant proteins, cytoplasmic extract and in vitro kinase assay are provided in SI Appendix.

Phos-tag polyacrylamide gel electrophoresis

Phos-tag polyacrylamide gel electrophoresis was performed essentially as described previously (27). For Phos-tag western blottings of ERK and p38, 5.0 x 10^{-5} and 1.5 x 10^{-4} M Phos-tag and 1.0 x 10^{-4} and 3.0 x 10^{-4} M MnCl₂ were added to conventional SDS-polyacrylamide separation gels according to the manufacturer’s protocol, respectively. Proteins were detected by using an Odyssey Infrared Imaging System (LI-COR).

Imaging

Live cell imaging was performed essentially as described (34).

Kinetic modeling and numerical simulation

Numerical simulation and parameter search were implemented by MATLAB software with ode23 and fminsearch function, respectively. The details are described in SI Appendix.

Immunostaining

Details of pTpY-ERK immunostaining are provided in SI Appendix.

Data analysis

For the determination of kinetic parameters, curve fitting were performed by the solver function
of Microsoft excel (Microsoft, WA).
Acknowledgments

We thank M. White, B. Neel, A. Miyawaki, T. Akagi, F. Ishikawa and J. Miyazaki for the plasmids. A. Nishiyama-Abe, R. Sakai, Y. Kasakawa, and N. Nonaka are also to be thanked for their technical assistance. We are grateful to the members of the Matsuda Laboratory for their helpful discussions. KA and MM were supported by Research Program of Innovative Cell Biology by Innovative Technology (Cell Innovation) from the Ministry of Education, Culture, Sports, and Science, Japan. KA was supported by the JST PRESTO program. MY and KK were supported by the Global COE Program "Center for Frontier Medicine" initiated by the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
References


31. Shilerman MD, Ding TT, & Lansbury PT, Jr. (2002) Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein


**Fig. legends**

**Fig. 1. ERK phosphorylation in vitro.** (A) Schematic representation of the input-output response of ERK MAP kinase. The distributive phosphorylation model leads to switch-like response. On the other hand, no model is currently validated for the graded response of ERK, which is observed in mammalian cells and yeast. (B) His-tagged MEK1-SDSE and GST-ERK2-KR were incubated with ATP for the indicated periods, followed by Phos-tag western blotting analysis. All phospho-isoforms of ERK were detected by anti-GST rabbit antibody (upper) and IRDye680-conjugated anti-rabbit IgG antibody as a secondary antibody. The positions of the phospho-isoforms of ERK are indicated at right (SI Appendix, Fig. S4). pTpY-ERK was simultaneously detected by anti-pTpY-ERK mouse antibody (middle) and IRDye800-conjugated anti-mouse IgG antibody as a secondary antibody. The lower image is the merged image (Red: ERK, Green: pTpY-ERK). (C) The phospho-isoforms of ERK were quantified and plotted with SD (n = 3).

**Fig. 2. Numerical and experimental analyses of the distributive phosphorylation model.** (A) Schematic representation of the distributive model (see SI Appendix, Fig. S8A in detail). (B and C) Results of numerical simulations are represented based on experimentally determined parameters (SI Appendix, Tables S1 and S2). (B) Concentrations of np-ERK (blue), pY-ERK (green), pTpY-ERK (red) and pT-ERK (orange) are plotted against time. The kcat/Km value of cRaf kinase for MEK phosphorylation (Raf_kphos) is $1.0 \times 10^6$ [M/sec]. (C) Concentrations of the phospho-isoforms of ERK are plotted against the Raf_kphos value at time = 10 [minutes]. (D
and E) After serum starvation, HeLa cells were stimulated with $1.0 \times 10^{-5}$ g/l EGF at the indicated time period. (D) Cell lysates were separated by SDS-polyacrylamide gel containing Phos-tag and probed with an anti-ERK antibody. (E) The amounts of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) are plotted against time after EGF stimulation with SD ($n = 3$). (F and G) After serum starvation, HeLa cells were stimulated with the indicated concentration of EGF for 7.5 min. (F) Cell lysates were analyzed by Phos-tag western blot analysis as in D. (G) The amounts of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) are plotted as a function of the EGF concentration with SD ($n = 5$).

**Fig. 3. Computational simulation of the processive phosphorylation model.** (A) Schematic representation of the processive model (see SI Appendix, Fig. S8B in detail). (B) Results of numerical simulations are represented based on experimentally determined parameters (SI Appendix, Tables S1 and S2). Time series of np-ERK (blue), pY-ERK (green), pTpY-ERK (red) and pT-ERK (orange) concentrations are plotted at Raf_kphos value $= 1.0 \times 10^6$ [/M/sec]. (C) Concentrations of the phospho-isoforms of ERK are plotted as a function of Raf_kphos value at time $= 10$ (min).

**Fig. 4. Validation of the processive model by pY-ERK dynamics.** (A and B) Numerical simulations were performed based on the distributive model (A) and the processive model (B) in the absence (left column) or presence of the inhibition of all phosphatase reactions (right column). Time series of np-ERK (blue), pY-ERK (green), pTpY-ERK (red) and pT-ERK (orange) concentrations are plotted at Raf_kphos value $= 1.0 \times 10^6$ [/M/sec]. Maximal levels of pY-ERK without inhibition are indicated by gray dashed lines. (C and D) After serum starvation, HeLa
cells were treated with mock or $1.0 \times 10^{-7}$ M Calyculin A and $1.0 \times 10^{-4}$ M bpV for 2 min, followed by $1.0 \times 10^{-5}$ g/l EGF for the indicated time period. (C) Cell lysates were separated by electrophoresis in SDS-polyacrylamide gels containing Phos-tag and probed with an anti-ERK antibody. (D) Time series of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) concentrations without (left) or with (right) phosphatase inhibitors are plotted after EGF stimulation with SD (n = 4).

**Fig. 5. Validation of the processive model by input-output response.** (A and B) Serum-starved HeLa cells were stimulated with the different concentration of EGF (blue, 0.01; cyan, 0.03; green, 0.1; yellow, 0.3; orange, 1.0; pink, 3.0; red, 10 (x $10^{-6}$ [g/l])) or $2.0 \times 10^{-5}$ M U0126 (black) for 5 min, and then stained with anti-pTpY-ERK1/2 antibody. (A) Fluorescent signals in each cell are represented in a histogram, demonstrating unimodal distributions (n > 90 cells). (B) The average fluorescent intensities are plotted as a function of EGF concentration with SD. Hill coefficient value, nH, was obtained by curve fitting with standard Hill equation (black line). (C) The average of fraction of pTpY-ERK are plotted as a function of EGF concentration with SD (n = 5). This data is same as shown in Fig. 2G (red line). (D) The average of fraction of pTpY-ERK was plotted as a function of ratio value of phosphorylated MEK1/2 to total MEK1/2 with SD (n = 5). (E and F) The pTpY-ERK concentration at time = 10 (min) after stimulation in distributive (E) and processive (F) model are plotted as a function of phosphorylated MEK concentration.

**Fig. 6. Effect of molecular crowding on processive phosphorylation.** (A and B) ERK was phosphorylated by MEK in the absence (A) or presence (B) of 15% (w/v) polyethylene glycol (PEG) in vitro and were subjected to Phos-tag western blotting analysis. (C and D) The
concentrations of phospho-isoforms of ERK in A and B are plotted as dots against time. Concentration of constitutively active mutant of MEK (1.0 x 10^{-7} M) used in these experiments is indicated by gray dashed lines. The same experiments were repeated four times with reproducible results, and representative results are shown. Lines represent the concentration of phospho-isoforms of ERK obtained by fitting the processive model in panel E with the experimental data. The fitted parameters of processivity (p) and crowding factor (c) are represented. (E) Schematic representation of processive phosphorylation. p and c indicate processivity (0<p<1) and crowding factor, respectively. (F) Schematic view of quasi-processive model under the condition of molecular crowding.
**A**  
In Vitro, Xenopus oocytes  
Distributive model  
![Diagram showing ERK signaling](image)

Switch-like response

Yeast, Mammalian cells  
![Diagram showing Graded response](image)

**B**  
In vitro kinase assay  
GST-ERK2-KR + MEK1-SDSE

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Input</th>
<th>Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10 sec</td>
<td>30 sec</td>
</tr>
</tbody>
</table>

**Phos-tag western blotting**

<table>
<thead>
<tr>
<th>Blot:</th>
<th>Anti-GST</th>
<th>Anti-pTpY-ERK</th>
</tr>
</thead>
<tbody>
<tr>
<td>KD</td>
<td>93</td>
<td>47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Red:</th>
<th>ERK</th>
<th>pY-ERK</th>
<th>np-ERK</th>
<th>pTpY-ERK</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Green:</th>
<th>pTpY-ERK</th>
</tr>
</thead>
</table>

**C**  
![Graph showing ERK concentration over time](image)

ERK (M)  
- np-ERK  
- pY-ERK  
- pTpY-ERK

Time (min)  
- 0 10 20 30
A Distributive model

- Phosphorylation
- Dephosphorylation

B

\[
\text{Raf}_\text{kphos} \quad (\text{M}/\text{sec})
\]

C

\[
\text{EGF} \quad (\text{g/l})
\]

D Endogenous

EGF stimulation (min)

- np-ERK2
- pY-ERK2
- pTpy-ERK2

<table>
<thead>
<tr>
<th>KD</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
<th>1.5</th>
<th>2</th>
<th>3</th>
<th>5</th>
<th>7.5</th>
<th>10</th>
<th>15</th>
<th>20</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>pY-ERK2</td>
<td>47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pTpy-ERK2</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Phos-tag western blotting

E

- np-ERK2
- pY-ERK2
- pTpy-ERK2

<table>
<thead>
<tr>
<th>EGF concentration (x10^-6 g/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05</td>
</tr>
<tr>
<td>np-ERK2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>KD</th>
<th>0</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.39</th>
<th>0.78</th>
<th>1.3</th>
<th>2.5</th>
<th>12.5</th>
<th>25</th>
<th>50</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Phos-tag western blotting

F Endogenous

EGF concentration (x10^-6 g/l)

- np-ERK2
- pY-ERK2
- pTpy-ERK2

G

- np-ERK2
- pY-ERK2
- pTpy-ERK2

<table>
<thead>
<tr>
<th>EGF (g/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10^-2</td>
</tr>
<tr>
<td>np-ERK2</td>
</tr>
</tbody>
</table>

Phos-tag western blotting
A. Stimulation vs. Stimulation + Phosphatase inhibition

- **Distributive model**
  - np-ERK
  - pY-ERK
  - pTpY-ERK
  - pT-ERK

- **Processive model**
  - np-ERK
  - pY-ERK
  - pTpY-ERK
  - pT-ERK

B. ERK Phosphorylation Levels

- **np-ERK**
- **pY-ERK**
- **pTpY-ERK**
- **pT-ERK**

C. Endogenous ERK Phosphorylation

- **EGF**
- **EGF + Calyculin A + bpV**

D. ERK Activity

- **EGF**
- **EGF + Calyculin A + bpV**

**Blot:**

- Anti-ERK1/2 KD 39
- Phos-tag western blotting

**Graphs:**

- Time (min) 0 2 4 6 8 10
- ERK (M) 0 2 4 6 8 10
- ERK (%) 0 25 50 75 100
A. Distribution model

B. Processive model

C. Experiments

D. Experiments

E. Distributive model

F. Processive model
**Rebining Binding Processive phosphorilation**

**A** In vitro

<table>
<thead>
<tr>
<th>Blot: KD</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>15</th>
<th>30</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-GST</td>
<td>93</td>
<td>47</td>
<td>47</td>
<td>93</td>
<td>120</td>
<td>120</td>
<td>120</td>
</tr>
</tbody>
</table>

Phos-tag western blotting

**B** In vitro

<table>
<thead>
<tr>
<th>Blot: KD</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>15</th>
<th>30</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-GST</td>
<td>93</td>
<td>47</td>
<td>47</td>
<td>93</td>
<td>120</td>
<td>120</td>
<td>120</td>
</tr>
</tbody>
</table>

Phos-tag western blotting

**C**

![Graph showing ERK, pY-ERK, and pTpY-ERK over time](image)

**D**

![Graph showing ERK, pY-ERK, and pTpY-ERK over time](image)

**E**

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Rate Equation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK → pY</td>
<td>c*(1-p)*k1</td>
</tr>
<tr>
<td>ERK → pT</td>
<td>c2k1</td>
</tr>
<tr>
<td>ERK → pYpT</td>
<td>c*k2</td>
</tr>
</tbody>
</table>

p: Processivity (0<p<1)
c: Crowding factor

**F**

- **Binding**
- **First phosphorylation**
- **Rebining**
- **Processive phosphorylation**

Diagram showing the process of rebining binding and processive phosphorylation.
Supporting Information:
Processive phosphorylation of ERK MAP kinase in mammalian cells.
Kazuhiro Aoki, Masashi Yamada, Katsuyuki Kunida, Shuhei Yasuda, and Michiyuki Matsuda

SI Text

Dephosphorylation rates of ERK in the cytoplasm and nucleus. We determined eight dephosphorylation rates of ERK, i.e., pTpY-ERK→pY-ERK, pTpY-ERK→pT-ERK, pY-ERK→np-ERK, and pT-ERK→np-ERK in each of two compartments, i.e., the cytoplasm and nucleus (Fig. S6). Because several phosphatases, including PTP1B, PP2A, and DUSPs, have reported to be involved in ERK dephosphorylation (1), we attempted to measure the rate constant [sec] of each dephosphorylation pathway for the cytoplasm and nucleus as the mass of phosphatases. To this end, we established HeLa cell lines stably expressing ERKs tagged with a nuclear export sequences (NES) or a nuclear localization signals (NLS). The cells were treated with EGF followed by an MEK inhibitor, PD184352, to measure the dephosphorylation rates (Fig. S6A, left column). Calyculin A, a serine/threonine phosphatase PP1/PP2A inhibitor, or bpV, a tyrosine phosphatase inhibitor, was also used to discriminate the two dephosphorylation reactions (Fig. S6A, center and right columns). Finally, the time constants for each dephosphorylation pathway were determined by curve-fitting the concentration of phospho isoforms of ERK with a single exponential decay function (Fig. S6B-K). Notably, we observed accumulation of pERK and pY-ERK in the presence of Calyculin A and bpV, respectively (Fig. S6A). This observation indicated that the dephosphorylation of pTpY-ERK was primarily mediated by serine/threonine phosphatases and tyrosine phosphatases, rather than dual-specificity phosphatases, at least in our experimental conditions. Furthermore, the dephosphorylation rate of MEK was also determined and included in our simulation model (Fig. S7). Of note, we neglected the effect of phosphatase inhibitors on Raf and MEK, because they will not affect the mode of ERK phosphorylation.

Involvement of Scaffold proteins in the processive model. Feasible candidates for the determinant of the processive phosphorylation include scaffold proteins, which regulate assembly of two or more components of signaling pathways and consequently change the mode of phosphorylation (2-6). To examine the contribution of scaffold proteins to the processive phosphorylation, we depleted KSR, MP-1, IQGAP1, Paxillin, or β-arrestin1/2 in HeLa cells by siRNA-mediated gene knockdown (7-11). The depletion of each scaffold protein could affect the phosphorylation efficiency of ERK in HeLa cells stimulated with EGF, but not alter the mode of ERK phosphorylation, namely processive phosphorylation, to the detectable level (Fig. S14). For this reason, at this moment, we failed to obtain any evidence that scaffold proteins cause processive phosphorylation in mammalian cells.

SI Materials and Methods

Plasmids. The cDNA of Xenopus MEK1 or Xenopus ERK2 was inserted into pCXN2-mVenus or pCXN2-mCFP vector to generate pCXN2-mVenus-MEK1, pCXN2-mCFP-MEK1, or pCXN2-mCFP-ERK2 (Fig. S2). Monomeric Venus (mVenus) or CFP (mCFP) was fused at the N-terminus of these vectors. The cDNA of FKBP (12) was introduced into these vectors to obtain pCXN2-mVenus-MEK1-FKBP and pCXN2-mVenus-ERK2-FKBP (Fig. S3). Threonine or tyrosine within the activation loop of ERK2 was replaced with alanine and phenylalanine, respectively, to obtain pCXN2-mVenus-ERK2T188A-FKBP and pCXN2-mVenus-ERK2Y190F-FKBP, respectively (Fig. S3). pCAGGS-FLAG-FRB-NES was designed to express FLAG tag, the FKBP-rapamycin-binding (FRB) domain of the mammalian target of rapamycin, and the nuclear export sequence (NES) of HIV rev protein (LQLPLERLTLID) from the N-terminus. The cDNAs of human Histon H1 (the kind gift of Dr. Ishikawa) and FRB were prepared by PCR and subcloned into pERedNLS vector (pERedNLS-H1-FRB) (13) (Fig. S3). The cDNA of mouse ERK2 or human MEK1 was subcloned into the modified pCX4bsr or pCX4puro vector (14) to generate pCX4bsr-NES-FLAG-ERK2-mVenus, pCX4bsr-FLAG-ERK2-mCFP-NLS, and pCX4puro-NLS-FLAG-MEK1. pCX4bsr-NES-FLAG-ERK2-mVenus encoded NES, FLAG tag, ERK2, and mVenus from the N-terminus (Fig. S6). pCX4bsr-FLAG-ERK2-mCFP-NLS was designed to express FLAG tag, ERK2, mCFP and the nuclear localization signal (NLS) of SV40 large T antigen (GGPKKPKKVKEDP). pCX4puro-NLS-FLAG-MEK1 encoded NLS, FALG tag and MEK1 from the N-terminus. A fragment of the kinase-deficient mutant of Xenopus ERK2 (ERK2-KR) was inserted into the pGEX4T3 vector to obtain pGEX4T3-ERK2-KR (Figs. 1, 6, S2, and S5). The cDNA of the wild type Xenopus MEK1 (MEK1WT), constitutively active mutant MEK1 (MEK1SDSE), or human PTP1B (the kind gift of Dr. B. Neel) was subcloned into the pET-12HisFLAG vector, which was designed to express double histidine hexamer-tagged FLAG peptide at the N-terminus (Figs. 1, 6, S2, S4, S5, and S12).

Cells, reagents and antibodies. HeLa cells were purchased from the Human Science Research Resources Bank (Sennan-shi, Japan). HeLa cells were maintained in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS). HEK-293F cells were purchased from Invitrogen (San Diego, CA), and maintained in FreeStyle 293 Expression Medium (Invitrogen). Expression plasmids were transfected into HeLa cells by 293Fectin (Invitrogen) according to the manufacturer’s instructions. EGF was purchased from Sigma-Aldrich. Calyculin A, bpV(phen), ZM336372, and
anisomycin were purchased from Calbiochem (La Jolla, CA). PD184352 was obtained from Toronto Research Chemicals (Ontario, Canada). Phos-tag acrylamide was obtained from the Phos-tag Consortium (http://www.phos-tag.com/). Fluorescent beads for calibration of Venus and CFP were purchased from Invitrogen (InSpeck Green (505/515) Microscope Image Intensity Calibration Kit) and from Polyscience (Fluoresbrite Plain YG 0.1 micron Microspheres) (Warrington, PA).

Anti-MEK1/2, anti-ERK1/2, anti-p38, anti-phospho-MEK1/2 (Ser177/187), anti-phospho-ERK1/2 (Thr202/Tyr204 and Thr185/Tyr187, respectively), and anti-phospho-p38 (Thr180/Tyr182) were purchased from Cell Signaling Technology (Beverly, MA). Anti-cRaf monoclonal antibodies came from BD Transduction Laboratories (San Jose, CA). Anti-pY-ERK and anti-pT-ERK monoclonal antibodies were purchased fromSigma. Anti-GFP and anti-GST rabbit sera were prepared in our laboratory (15, 16). LI-COR blocking buffer, IRDye680- and IRDye800-conjugated anti-rabbit and anti-mouse IgG secondary antibodies were obtained from LI-COR Bioscience (Lincoln, NE). Polyethylene glycol 6000 was purchased from Hampton Research (Aliso Viejo, CA).

Establishment of stable cell lines. For generation of HeLa cell lines stably expressing ectopic proteins, we utilized a retroviral system. The murine ectopic retrovirus receptor (EcoVR) was first introduced into HeLa cells by retroviruses produced from BOSC23 cells, which had been transfected with pCX4hyg-EcoVR, the packaging plasmid pGP, and the envelope plasmid pSVSV-G (14). The HeLa cells stably expressing EcoVR were selected by Hygromycin. Then, HeLa-EcoVR cells were infected with retroviruses obtained from pCX4bsr-NES-FLAG-ERK2-mVenus-, pCX4bsr-FLAG-ERK2-mCFP-NLS-, or CX4puro-NLS-FLAG-MEK1-transfected BOSC23 cells (Fig. S6).

Recombination of recombinant proteins and in vitro kinase assay. Recombinant proteins fused to GST-tag and His-tag were expressed in E. coli strain BL21-DE3 from pGEX- and pET-derived vectors and purified as described previously (16). GST-tagged human MEK1, GST-tagged human ERK2, and GST-tagged human cRaf deleted with the N-terminus (kinase active mutant) were purchased from Millipore (Bedford, MA). For preparation of GST-pERK2, plasmids of both pGEX-ERK2-KR and pET-12HisFLAG-MEK1SDSE were cotransformed into E. coli strain BL21-DE3. Fully phosphorylated-GST-ERK2 (pTyr-ERK2) was purified and incubated with recombinant 12HisFLAG-PTP1B to dephosphorylate phospho-tyrosine in dephosphorylation buffer (100 mM Tris [pH 7.5], 100 mM NaCl, 1 mM EDTA, 2 mM DTT). The GST-pERK2 was then further purified. For in vitro kinase assay, GST-ERK2 or pTyr-ERK2 with 12HisFLAG-MEK1SDSE was incubated in in vitro kinase buffer (50 mM Tris [pH 7.5], 10 mM MgCl2, 0.02% BSA 0.2 mM DTT). The reaction was started by adding 5 x ATP solution (5 mM ATP, 50 mM MgCl2, 25 mM Tris [pH 7.2], 0.15 M NaCl) and stopped at the indicated time point by adding SDS sample buffer.

Preparation of cytoplasmic extract. For preparation of cytoplasmic extract, HEK-293F cells were collected by centrifugation. The packed cells were snap-frozen, followed by rapid thawing in water bath. After centrifugation, the supernatant was collected and used as cytoplasmic extract. The extract was diluted 10-fold for in vitro kinase reaction.

Immunostaining. Cells were fixed with 3.7% formaldehyde and permeabilized with 0.2% Triton X-100. After having been soaked for 1 h in phosphate-buffered saline (PBS) containing 3% BSA and 0.02% Triton X-100, the samples were incubated for 1 h at room temperature with 5 µg/ml anti-pTyr-ERK antibodies, washed with PBS, and then incubated for 30 min at room temperature with Alexa 488 anti-mouse IgG. The samples were washed with PBS containing 0.2% Tween 20, and imaged with an Olympus FV1000 microscope.

Measurement of the dissociation constant by intermolecular FRET assay. First, images of YFP, CFP, and FRET were acquired, and then corrected FRET (cFRET) images were created by subtracting the contributions of cross-excitation and bleed-through as follows:

$$cFRET = \frac{FRET - (0.089 \cdot [YFP]) - (0.55 \cdot [CFP])}{0.16 \cdot 0.57},$$

where 0.089 and 0.55 indicate the degree of cross-excitation and spectral bleed-through under our microscopic conditions, respectively (17). cFRET and the cFRET/YFP ratio indicate the amount of bound protein and the fraction of acceptor protein that contribute to FRET, respectively. Concentrations of fluorescent proteins were evaluated by calibrated fluorescent beads as described previously (18). The fraction of ERK-bound MEK (Bound MEK/Total MEK) in individual cells was calculated as follows:

$$\frac{Bound\ MEK}{Total\ MEK} = 1 - \frac{cFRET}{0.16 \cdot 0.57 \cdot [YFP]}.$$

In vitro binding assay. Various concentration of GST-ERK2KR and 100 nM 12His-FLAG-MEK1WT were incubated with in vitro binding buffer (PBS, 0.1% Tween-20, 1 mM MgCl2, 40 mM imidazole). Bound protein was pulled down by Ni-NTA agarose beads (Qiagen, Valencia, CA), washed with in vitro binding buffer three times, and eluted with 200 mM imidazole-containing PBS. Each eluate was analyzed by SDS-PAGE and western blotting.

Surface plasmon resonance assay. Surface plasmon resonance spectroscopy was performed with a BIACore-X optical biosensor instrument (Biacore AB, Uppsala, Sweden)
using a NTA sensor chip (NTA bound to a solid support) as described previously (20). Briefly, surface plasmon resonance buffers were as follows: (i) regeneration buffer: 10 mM Hapes, 0.15 M NaCl, 0.35 M EDTA, pH 7.4; (ii) nickel buffer: 500 μM NiSO₄ in running buffer; (iii) running buffer: PBS with 1 mM MgCl₂, 0.1 % (v/v) Surfactant 20, pH 7.4. Ligand (12His-tagged MEK1WT) and analyte (GST-tagged ERK2KR) were dissolved in running buffer. All reactions were done at 25 °C. The data were analyzed using BIAevaluation 3.0 software (Biacore AB) and kinetic analyses of primary sensorgrams were carried out by global fitting using a modified-heterogeneous binding model to consider non-specific binding of the analyte to Ni-NTA chip sensor.

**Nucleocytoplasmic shuttling of MEK and ERK.** To measure nuclear import and export rates, we used a rapamycin-induced dimerization system of an FK506-binding protein (FKBP12 or FKBP) and FRB domain. For measurement of nuclear import rates, Histone H1-fused FRB (H1-FRB) was employed as a binder for FKBP-fused proteins. Similarly, the nuclear export rate of ERK was determined with an FRB fused to the nuclear export sequence (NES). We measured nuclear import and export rates of phospho-isomers of ERK as follows: phosphorylation of ERK2T188A or ERK2Y190F was induced by the stimulation of EGF and bpV for 10 min. Then, Rapamycin was added to the cells in order to trap phosphorylated ERK in nucleus or cytoplasm. The fraction of MEK-dependent active nuclear export of ERK was ignored, because the nuclear import rate of MEK (4.0 x 10⁻⁹ [sec⁻¹]) was considerably slower than the nuclear import and export rates of ERK under the time scale used in our simulation model (~30 min). From these data, we show that pTPy-ERK seems to be actively imported into the nucleus. Unexpectedly, the nuclear export rate of p-ERK is larger than those of the other phospho-isomers. Thus, both the fast import of pTPy-ERK and the fast export of p-ERK contribute to the increase in pTPy-ERK accumulation in HeLa cells.

**Phosphorylation rates of ERK in vitro.** Each experiment included a series of diluted GST-ERK concentration as shown in Fig. S5. These eluates were subjected to Phos-tag western blotting. The amounts of phospho-isomers of ERK were quantified and fitted by global least-square regression algorithm to solutions of following differential equations with Microsoft Excel Solver:

\[
dp{[np - ERK]}{t} = -k_f_1 \cdot [MEK] \cdot [np - ERK]
\]

\[
dp{[pY - ERK]}{t} = k_f_2 \cdot [MEK] \cdot [pY - ERK] - k_f_1 \cdot [MEK] \cdot [pY - ERK] - k_f_0 \cdot [pY - ERK]
\]

where [MEK], [np-ERK], [pY-ERK], and [pTPyHk] are concentration of MEK, np-ERK, pY-ERK, and pTPy-ERK, respectively. k1 and k2 are phosphorylation rate constants [M/sec], which are enzymatically identical to kcat/Km at substrate concentrations significantly lower than Km. Initial velocity of the phosphorylation was plotted against the substrate concentration (Fig. S5C). The initial velocity was not saturated up to 1.5 x 10⁻⁸ M, indicating that the Michaelis constant of the first phosphorylation step is over this range. Therefore, we assumed the linear reaction rates of ERK phosphorylation at least in the range of ERK concentrations.

**siRNA for scaffold proteins and quantitative RT-PCR.** Scramble siRNA and validated siRNAs for human KSR1 (#1 and #2) were purchased from Invitrogen (San Diego, CA). siRNAs for human MP1, IQGAP1, Paxillin, β-arrestin1, and β-arrestin2 were obtained Santa Cruz Biotechnology (Santa Cruz, CA). HeLa cells were transfected with 20 μM control siRNA or siRNA for a scaffold protein by Lipofectamine RNAiMAX (Invitrogen). Three days after transfection, total RNA was purified by RNAeasy Mini Kit (Qiagen, Hilden, Germany), and reverse-transcribed by High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol. Then, expression levels of scaffold protein and GAPDH were analyzed by SYBR GreenER qPCR SuperMix (Invitrogen) with ABI PRISM7000 Sequence Detection System (Applied Biosystems). Primers used for real time PCR analysis were listed as follows: GAPDH: (Fw) 5'-GAGTCACCTGGCGTCTCAG-3' and (Rv) 5'-GTCACACCCCATGACGAACTT-3', KSR1: (Fw) 5'-TCTCCACCCCTGGAACATTT-3' and (Rv) 5'-GAGAAGAAGACCCCTGGT-3', MP1: (Fw) 5'-GGTTCAGAAGATGAGAGTCTAGT-3' and (Rv) 5'-AAACAGGTGGCAAAGCATG-3', IQGAP1: (Fw) 5'-TGTGCAAATCTGTAGCCTT-3' and (Rv) 5'-GCGAGTCACCCCATGACGAGCT-3', Paxillin: (Fw) 5'-CAGCAGACACGCTCCTCG-3' and (Rv) 5'-GAGCTGCTCCGTGCTCTCC-3', β-arrestin1: (Fw) 5'-ACTATGAAGTCAAAGCCTTGTC-3' and (Rv) 5'-GGATGACCAGCAGCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
number of parameters for optimization were utilized to calculate Akaike information criterion (AIC) value for ranking which of models was reasonable (23).

**SI References**

Fig. S1. Quantification of protein concentrations, dissociation constant, and nucleocytoplasmic shuttling rates. (A and B) For the determination of the molecule numbers of MEK and ERK, serial dilution of recombinant GST-tagged proteins and total cell lysates of HeLa cells were separated by SDS-PAGE, followed by immunoblotting with anti-MEK1/2 (A) and anti-ERK1/2 (B) antibodies. The bound antibodies were detected and quantified. (C and D) The bands in A and B were quantified and plotted as scatter plots, showing the linear relation between intensity and dilution of molecules and cell number. (E) For quantification of the volume of the cytoplasm and nucleus, HeLa cells were trypsinized and stained with Hoechst 33258. Cells were imaged with differential interference contrast microscopy (upper, cytoplasm and nucleus) or fluorescence microscopy (lower, nucleus).
Fig. S2. Measurements of dissociation constant for the binding of MEK and ERK. (A) HeLa cells were transfected with plasmids encoding mVenus-MEK1 and mCFP-ERK2 as indicated ratio. Images of YFP, CFP and FRET were acquired two days after transfection. Then, corrected FRET image (cFRET) images were created by several corrections described in SI Materials and Methods. cFRET/YFP ratio images are shown in the intensity-modulated display mode, in which eight colors from red to blue are used to represent the cFRET/YFP ratio with the intensity of each color indicating the mean intensity of cFRET and YFP. The upper and lower limits of the ratio range are shown in the bottom. (B) Fraction of ERK-bound MEK (Bound MEK/Total MEK) versus the concentration of free ERK in each cell is plotted with the fitted curve. The dissociation constant was calculated as described in SI Materials and Methods. (C) Dissociation constant between MEK and ERK was measured by using in vitro binding assay. (D) The amount of bound versus free ERK is plotted with the fitted curve (Kd is 1.5 x 10^-6 M). (E) Interaction between MEK and ERK was monitored in real time by surface plasmon resonance spectroscopy analysis. Increasing concentrations of ERK (0.25-4.0 x 10^-6 M) were passed over a sensor chip with immobilized MEK for 60 s (association phase) before the flow was switched to buffer alone for another 60 s (dissociation phase). Association and dissociation rate constants were derived using BIAevaluation 4.1 software.
Fig. S3. Measurements of nucleocyttoplasmic shuttling rates of phospho-isoforms of ERK. (A) HeLa cells expressing mVenUS/FKBP-tagged ERK wild type (WT), T188A, or Y190F were serum-starved for 6-12 h and stimulated with $2.0 \times 10^{-6}$ g/l EGF and $1.0 \times 10^{-4}$ M bpV for 10 min. Cells were lysed and subjected to Phos-tag western blotting with anti-GFP antibody. The four phospho-isoforms of ERK are indicated on the right: np, non-phosphorylated; pT, threonine mono-phosphorylated; pY, tyrosine mono-phosphorylated; pTpY, threonine and tyrosine bis-phosphorylated (see Fig. S4 in detail). (B and C) HeLa cells expressing the proteins indicated at the bottom were stimulated with 2.0 x 10^{-6} g/l EGF and 1.0 x 10^{-4} M bpV for 10 min, followed by the addition of 2.5 x 10^{-3} M Rapamycin to trap the proteins at nucleus (B) or cytoplasm (C). (D and E) After Rapamycin treatment, the nuclear fluorescence intensity was monitored and fitted with single (np-ERK), double (pY-ERK, pT-ERK), or triple (pTpY-ERK) exponential curves. The fraction of each exponential curve was determined from the data shown in A. The nuclear import (D) and export (E) rates of each phospho-isoform was obtained from the time constants of the exponential curves.
Fig. S4. Separation of phospho-isoforms of ERK by phospho-affinity gel electrophoresis. (A) GST-tagged Xenopus ERK2-KR (K57R, kinase-dead mutant) was phosphorylated in vitro by His-tagged Xenopus MEK1-SDSE (constitutively active mutant) for the indicated periods. Phosphorylated proteins were identified by Phos-tag western blot analysis with anti-ERK1/2 (upper and lower), anti-pTpY-ERK1/2 (upper), and anti-pY-ERK1/2 antibodies (lower). Non-phosphorylated ERK (np-ERK), tyrosine mono-phosphorylated ERK (pY-ERK), and tyrosine and threonine bis-phosphorylated ERK (pTpY-ERK) are denoted on the right. (B) GST-pTpY-ERK2 was dephosphorylated by His-tagged PTP1B to generate pT-ERK2. Phosphorylated proteins were analyzed by using anti-ERK1/2 (upper and lower), anti-pTpY-ERK1/2 (upper), and anti-pT-ERK1/2 antibodies (lower).
**Fig. S5.** Measurement of phosphorylation rates *in vitro.* (A) GST-ERK2-KR at the indicated concentrations was phosphorylated by His-tagged MEK1-SDSE (3.0 x 10⁻⁷ M) in the presence of 1.0 x 10⁻³ M ATP for the indicated time period, followed by Phos-tag western blot analysis. Non-phosphorylated ERK (np-ERK), tyrosine mono-phosphorylated ERK (pY-ERK), and tyrosine and threonine bis-phosphorylated ERK (pTpY-ERK) are denoted on the right. (B) The amounts of phospho-isomers of ERK were quantified by subtracting the amount of non-reactive ERK, and plotted as circles. The data were fitted by a global least-square regression algorithm to a two-steps first-order phosphorylation model to obtain kinetic parameters. (C) The initial velocity of the first phosphorylation step is plotted against the substrate concentration. The velocity is not saturated in up to 1.5 x 10⁻⁶ M of substrate, indicating that the Michaelis constant of this phosphorylation step is larger than this range. (D) A Lineweaver-Burk plot of the first phosphorylation step is shown with the linear regression line. (E) GST-pT-ERK2-KR was phosphorylated by His-tagged MEK1-SDSE in the presence of 1.0 x 10⁻³ M ATP for the indicated period, followed by Phos-tag western blot analysis. (F) The amounts of phospho-isomers of ERK were quantified and plotted. The data were fitted to a one-step first-order phosphorylation model to obtain kinetic parameters. (G) Schematic diagram of distributive ERK phosphorylation.
Fig. S6

A Exogenous HeLa / NES-ERK2-mVenus

B

C

D Cytosol

E Nucleus

F

G

H

I

J

K

Fig. S6. Measurement of the dephosphorylation rate of ERK. (A) HeLa cells stably expressing NES-ERK2-mVenus (upper) or ERK2-mCFP-NLS with NLS-MEK1 (lower) were serum starved for 12 hours. Cells were left untreated or treated with 1.0 x 10^{-5} g/l EGF for 5 minutes, followed by 1.0 x 10^{-5} M PD184352 with mock (left), 1.0 x 10^{-5} M Calyculin A (center) or 1.0 x 10^{-4} M bpV (right) for the indicated time periods. Cell lysates were subjected to Phos-tag western blot analysis using anti-GFP and anti-pT-pY-ERK antibodies. We repeated the same experiments four times with reproducible results, and representative results are shown. (B) Scheme of two dephosphorylation pathways for pT-pY-ERK. (C) The decrease of pT-pY-ERK after MEK inhibition by PD184352 in the presence or absence of Calyculin A was monitored in cytosol (upper) and nucleus (lower). Bars are SD (n = 4). (E and F) The dephosphorylation rates [1/sec] in cytosol (D) and nucleus (E) were measured by fitting the time course of pT-pY-ERK decay shown in C with an exponential decay function. Dephosphorylation rates from pT-pY-ERK to pT-ERK were simply interpreted as the decay rates with Calyculin A. Dephosphorylation rates from pT-pY-ERK to pY-ERK were obtained by subtracting total dephosphorylation rates from those of pT-pY-ERK to pT-ERK. (F) Scheme of dephosphorylation pathways for pY-ERK. Calyculin A prevents an influx of pY-ERK via pT-pY-ERK. (G) The decrease of pY-ERK upon MEK inhibition by PD184352 in the presence of Calyculin A was monitored in cytosol (left) and nucleus (right). Bars are SD (n = 4). (H) The dephosphorylation rates [1/sec] in cytosol and nucleus were measured by fitting the time course of pY-ERK decay with an exponential function. (I) Scheme of dephosphorylation pathways for pT-ERK. bpV prevents an influx of pT-pY-ERK. (J) The decrease of pT-ERK upon MEK inhibition by PD184352 in the presence of bpV was monitored in cytosol (left) and nucleus (right). Bars are SD (n = 4). (K) The dephosphorylation rates [1/sec] in cytosol and nucleus were measured by fitting the time course of pT-ERK decay with an exponential function. See SI Text in more details.
**Fig. S7.** Measurement of the dephosphorylation rate of MEK. To measure the MEK dephosphorylation rate in HeLa cells, we generated a HeLa cell line stably expressing cRaf-FKBP and LDR. Upon Rapamycin treatment of this cell line, cRaf-FKBP is recruited to plasma membrane and activated rapidly. Consequently, MEK is phosphorylated by the cRaf-FKBP without any perturbations of other signaling pathways. (A) The HeLa cells were left untreated or pretreated with a cRaf inhibitor, ZM336372, for 10 min, and then stimulated with Rapamycin for 30 min. The cell lysates were subjected to SDS-PAGE and analyzed by anti-phospho-MEK1/2 (upper) and anti-MEK1/2 (lower) antibodies. (B and C) Measurement of the dephosphorylation rate of MEK. (B) The aforementioned HeLa cells were treated with or without Rapamycin for 15 min, and then treated with ZM336372 for the indicated time period. The cell lysates were collected and subjected to SDS-PAGE followed by immunoblotting analysis with anti-phospho-MEK1/2 (upper) and anti-MEK1/2 (lower) antibodies. These experiments were repeated three times and representative results are shown. (C) The relative amount of phosphorylated MEK1/2 was measured and plotted as a function of time after ZM336372 addition (min). The decay of MEK is fitted to the red line with a single exponential decay function.
Fig. S8. Diagram of the distributive and processive model. (A) A process diagram of the distributive phosphorylation model of the MEK-ERK module was represented. The arrows represent the reactions (Re), which are numbered from 1 to 17 as described in the Table S2. (B) A process diagram of the processive phosphorylation model of the MEK-ERK module. The arrows represent the reactions (Re), which are numbered from 1 to 20 as described in the Table S2. Blue numbers are common between the distributive model and the processive model. Red numbers are reactions specific to the processive model.
Fig. S9. Dynamics of ERK phosphorylation with varying MEK activity. Experimentally-determined parameters were used for the numerical simulations based on the distributive model and processive model. (A) Heat maps of the concentration of phosphorylated MEK upon stimulation in distributive model (left) and processive model (right). Horizontal and vertical axes indicate time after stimulation (minute) and kcat/Km value (Raf_kphos) of cRaf kinase for MEK phosphorylation as an input strength, respectively. (B) HeLa cells were stimulated with 1.0 x 10^{-5} g/l EGF, and lysed with SDS sample buffer at the indicated time points. The cell lysates were subjected to Western blotting analysis with anti-MEK1/2 and anti-phospho-MEK1/2 antibodies. The ratio of phospho-MEK to MEK (pMEK/MEK) is plotted against the time after EGF stimulation (red circle). In addition, the time course of MEK phosphorylation in the distributive model at kcat/Km value of 1.0 x 10^{6} [M/sec] is superimposed in the same figure. (C and D) Shown here are the heat maps of the concentration of the indicated phospho-isoforms of ERK upon stimulation in the distributive model (C) and processive model (D).
Fig. S10

**A** Distributive model

**B** Processive model

**Fig. S10.** Dynamics of ERK phosphorylation in the absence of dephosphorylation pathways. Shown here are heat maps of concentration of the indicated phospho-isoforms of ERK upon stimulation in the distributive model (A) and processive model (D) as well as shown in Figure S9 except for the lack of dephosphorylation pathways.
**Fig. S11**

**A**

Condition 1

Distributive model

\[ \text{ERK} \xrightarrow{\text{const}} \text{pY-ERK} \]

Processive model

\[ \text{ERK} \xrightarrow{\text{const}} \text{pY-ERK} \]

Condition 2

Distributive model

\[ \text{ERK} \xrightarrow{\text{p1}} \text{pT-pY-ERK} \]

Processive model

\[ \text{ERK} \xrightarrow{\text{p3}} \text{pT-pY-ERK} \]

Condition 3

Distributive model

\[ \text{ERK} \xrightarrow{\text{p4}} \text{pT-pY-ERK} \]

Processive model

\[ \text{ERK} \xrightarrow{\text{p7}} \text{pT-pY-ERK} \]

**B**

Figure 2

**Without inhibitor**

**With inhibitor**

**C**

<table>
<thead>
<tr>
<th></th>
<th>Distributive model</th>
<th>Processive model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RSS</td>
<td>AIC</td>
</tr>
<tr>
<td>Condition 1</td>
<td>1.165</td>
<td>-36.3</td>
</tr>
<tr>
<td>Condition 2</td>
<td>0.382</td>
<td>-49.0</td>
</tr>
<tr>
<td>Condition 3</td>
<td>0.204</td>
<td>-42.5</td>
</tr>
</tbody>
</table>

**Fig. S11. Numerical validation of the processive phosphorylation model.** (A) Numerical validation of the phosphorylation models by parameter fittings. (A) The conditions for the parameter fittings are illustrated. Black lines represent reactions to be optimized by parameter search. Condition 1 (left) aims to fit the data (Fig. 2E and Fig. 4D) by optimizing the quantity of the activated MEK; therefore the models have only 1 degree of freedom. Condition 2 (middle) aims to fit the data by independently changing the MEK activities against np-ERK, pY-ERK, and pT-ERK, allowing 3 and 4 degrees of freedom in the distributive and processive models, respectively. Condition 3 (right) aims to fit the data by changing all phosphorylation and dephosphorylation rates, allowing 11 and 12 degrees of freedom in the distributive and processive models, respectively. (B) The results of curve fitting are shown with the experimental data in Fig. 2E and Fig. 4D. (C) A table presents a summary of the parameter fitting. RSS, AIC, and nH refer to residual sum of square, Akaike information criterion, and Hill coefficient, respectively. Based on the AIC and Hill coefficient values, the processive model in Condition 2 is the most plausible model. In Condition 3, even though the AIC value of the distributive model is comparable to that of the processive model, the AIC value is much larger than that obtained for the processive model in Condition 2, suggesting over-fitting.
**Fig. S12.** In vitro ERK phosphorylation by using cell extract. Cytoplasmic extract prepared from HEK-293F cells were diluted with in vitro kinase buffer containing ATP and constitutively active MEK, and incubated for the indicated period (min). (A) The reaction solution were subjected to Phos-tag western blotting analysis. (B) The fractions of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) are plotted against time.

**Fig. S13.** Processive phosphorylation of p38 MAP kinase. (A) HeLa cells were stimulated with 1.0 x 10^{-3} g/l anisomycin at the indicated time. Cell lysates were subjected to Phos-tag western blot analysis. (B) HeLa cells were stimulated with indicated concentration of anisomycin for 30 min. Cell lysates were subjected to Phos-tag western blot analysis. (C and D) The phospho isoforms of p38 in A and B were quantified and plotted. Notably, preceding accumulation of pY-p38, which was typical hallmark of distributive phosphorylation, was not observed in time-course (C) and steady-state (D) analysis.
Fig. S14

(A) Endogenous

<table>
<thead>
<tr>
<th></th>
<th>Control (KD: 81%)</th>
<th>KSR1 #1 (KD: 61%)</th>
<th>KSR1 #2 (KD: 44%)</th>
<th>MP1 (KD: 92%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blot:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phos-tag western blotting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Red: ERK1/2</td>
<td>pY-ERK2</td>
<td>pY-ERK2</td>
<td>pY-ERK2</td>
</tr>
<tr>
<td></td>
<td>Green: pTpY-ERK1/2</td>
<td>pTpY-ERK1/2</td>
<td>np-ERK2</td>
<td>np-ERK2</td>
</tr>
</tbody>
</table>

Fig. S14. Effects of scaffold proteins on the mode of ERK phosphorylation. (A) HeLa cells were transfected with siRNA for control or scaffold proteins as indicated. Three days after transfection, the HeLa cells were stimulated with 1.0 x 10^{-5} g/l EGF and analyzed at the indicated time. Cells were subjected to Phos-tag western blot analysis. Knockdown efficiency (KD, %) of siRNA was determined by quantitative RT-PCR analysis. (B) The phospho-isoforms of ERK quantified in A are plotted with SD (n = 3). See SI Text in more details.
Table S1

Table S1. Concentration of cRaf, MEK, and ERK in a HeLa cell.

<table>
<thead>
<tr>
<th>Species</th>
<th>Concentration (M)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average</td>
<td>SD</td>
</tr>
<tr>
<td>cRaf</td>
<td>1.3 x 10^{-8}</td>
<td>-</td>
</tr>
<tr>
<td>MEK</td>
<td>1.2 x 10^{-6}</td>
<td>5.2 x 10^{-7}</td>
</tr>
<tr>
<td>ERK</td>
<td>7.4 x 10^{-7}</td>
<td>3.3 x 10^{-7}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Volume (l)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average</td>
<td>SD</td>
</tr>
<tr>
<td>Cytoplasm</td>
<td>2.8 x 10^{-12}</td>
<td>7.6 x 10^{-13}</td>
</tr>
<tr>
<td>Nucleus</td>
<td>6.0 x 10^{-13}</td>
<td>2.1 x 10^{-13}</td>
</tr>
</tbody>
</table>

MEK and ERK mean the total concentration of both MEK1 and MEK2 and both ERK1 and ERK2, respectively.
Table S2

Table S2. Kinetic models and parameters.

<table>
<thead>
<tr>
<th>Reaction #</th>
<th>Reaction</th>
<th>Parameters</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Average</td>
<td>SD</td>
</tr>
<tr>
<td>Re1</td>
<td>MEK + cRaf &lt;-&gt; pMEK</td>
<td>kf</td>
<td>1.0 x 10⁶</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>9.6 x 10⁻³</td>
</tr>
<tr>
<td>Re2</td>
<td>MEK + np-ERK_cyt &lt;-&gt; MEK_np-ERK</td>
<td>kf</td>
<td>1.8 x 10⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>2.7 x 10⁻¹</td>
</tr>
<tr>
<td>Re3</td>
<td>np-ERK_cyt &lt;-&gt; np-ERK_nuc</td>
<td>kf</td>
<td>1.7 x 10⁻³</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>1.3 x 10⁻²</td>
</tr>
<tr>
<td>Re4</td>
<td>pY-ERK_cyt &lt;-&gt; pY-ERK_nuc</td>
<td>kf</td>
<td>2.5 x 10⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>1.7 x 10⁻²</td>
</tr>
<tr>
<td>Re5</td>
<td>pT-ERK_cyt &lt;-&gt; pT-ERK_nuc</td>
<td>kf</td>
<td>2.2 x 10⁻³</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>4.9 x 10⁻²</td>
</tr>
<tr>
<td>Re6</td>
<td>pTPY-ERK_cyt &lt;-&gt; pTPY-ERK_nuc</td>
<td>kf</td>
<td>8.2 x 10⁻³</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>7.6 x 10⁻³</td>
</tr>
<tr>
<td>Re7</td>
<td>pTPY-ERK_cyt &lt;-&gt; pY-ERK_cyt</td>
<td>kf</td>
<td>4.0 x 10⁻³</td>
</tr>
<tr>
<td>Re8</td>
<td>pTPY-ERK_cyt &lt;-&gt; pT-ERK_cyt</td>
<td>kf</td>
<td>5.5 x 10⁻³</td>
</tr>
<tr>
<td>Re9</td>
<td>pY-ERK_cyt &lt;-&gt; np-ERK_cyt</td>
<td>kf</td>
<td>6.7 x 10⁻³</td>
</tr>
<tr>
<td>Re10</td>
<td>pT-ERK_cyt &lt;-&gt; np-ERK_cyt</td>
<td>kf</td>
<td>6.8 x 10⁻³</td>
</tr>
<tr>
<td>Re11</td>
<td>pTPY-ERK_nuc &lt;-&gt; pY-ERK_cyt</td>
<td>kf</td>
<td>3.2 x 10⁻³</td>
</tr>
<tr>
<td>Re12</td>
<td>pTPY-ERK_nuc &lt;-&gt; pT-ERK_cyt</td>
<td>kf</td>
<td>3.8 x 10⁻³</td>
</tr>
<tr>
<td>Re13</td>
<td>pY-ERK_nuc &lt;-&gt; np-ERK_nuc</td>
<td>kf</td>
<td>7.7 x 10⁻³</td>
</tr>
<tr>
<td>Re14</td>
<td>pT-ERK_nuc &lt;-&gt; np-ERK_nuc</td>
<td>kf</td>
<td>5.8 x 10⁻³</td>
</tr>
<tr>
<td>Re15</td>
<td>np-ERK_cyt + pMEK &lt;-&gt; pY-ERK_cyt</td>
<td>kf</td>
<td>3.9 x 10⁴</td>
</tr>
<tr>
<td>Re16</td>
<td>pY-ERK_cyt + pMEK &lt;-&gt; pTPY-ERK_cyt</td>
<td>kf</td>
<td>2.1 x 10⁴</td>
</tr>
<tr>
<td>Re17</td>
<td>pT-ERK_cyt + pMEK &lt;-&gt; pTPY-ERK_cyt</td>
<td>kf</td>
<td>2.0 x 10⁴</td>
</tr>
<tr>
<td>Re18</td>
<td>pMEK + np-ERK_cyt &lt;-&gt; pMEK_np-ERK</td>
<td>kf</td>
<td>1.8 x 10⁵</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kb</td>
<td>2.7 x 10⁻¹</td>
</tr>
<tr>
<td>Re19</td>
<td>pMEK_np-ERK &lt;-&gt; pMEK_pY-ERK</td>
<td>kf</td>
<td>7.3 x 10⁻²</td>
</tr>
<tr>
<td>Re20</td>
<td>pMEK_pY-ERK &lt;-&gt; pMEK + pMEK_cyt</td>
<td>kf</td>
<td>5.0 x 10⁻²</td>
</tr>
</tbody>
</table>

The reaction number is indicated in Figure S8A and S8B. Bold character means enzyme. The symbols <-> and -> indicate a reversible reaction and an irreversible reaction, respectively. kf and kb are forward and reverse kinetic parameters, respectively.

¹ kf and kb are obtained by Biacore with 5 different sets of ligand concentration. Dissociation constants, which are measured by FRET and in vitro binding assay, are 1.7 x 10⁻⁶ ± 6.8 x 10⁻⁷ [M] (N = 3) (Fig. S2A and B) and 1.8 x 10⁻⁶ [M] (N = 1) (Fig. S2C and D), respectively.

² Parameters are obtained by global fitting of 2 independent experiments with 10 different sets of substrate and enzyme concentration.

³ Assuming that the association/dissociation rate constants of the binding between pMEK and ERK are comparable with the association/dissociation rate constants of the binding between MEK and ERK.

⁴ kcat/Km = kcat/(kb+kcat)/kf, and then 0.038 = kcat/(0.27+kcat)/1.8. Thus, kcat = 0.79.
Table S3

Table S3. Summary of parameters fitted with three different conditions in Figure S11.

<table>
<thead>
<tr>
<th>Reaction #</th>
<th>Reaction</th>
<th>Initial value (Unit)</th>
<th>Fitting condition 1</th>
<th>Fitting condition 2</th>
<th>Fitting condition 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Re7</td>
<td>pTpY-ERK_cyt -&gt; pY-ERK_cyt</td>
<td>kf 4.0 x 10^{-3} /sec</td>
<td>6.5 x 10^{-3}</td>
<td>9.2 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re8</td>
<td>pTpY-ERK_cyt -&gt; pT-ERK_cyt</td>
<td>kf 5.5 x 10^{-3} /sec</td>
<td>-6.1 x 10^{-3}</td>
<td>-3.0 x 10^{-4}</td>
<td></td>
</tr>
<tr>
<td>Re9</td>
<td>pY-ERK_cyt -&gt; np-ERK_cyt</td>
<td>kf 6.7 x 10^{-3} /sec</td>
<td>6.8 x 10^{-3}</td>
<td>1.2 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re10</td>
<td>P-ERK_cyt -&gt; np-ERK_cyt</td>
<td>kf 6.8 x 10^{-3} /sec</td>
<td>7.7 x 10^{-3}</td>
<td>1.0 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re11</td>
<td>pTpY-ERK_nuc -&gt; pY-ERK_nuc</td>
<td>kf 3.2 x 10^{-3} /sec</td>
<td>1.0 x 10^{-3}</td>
<td>2.8 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re12</td>
<td>pTpY-ERK_nuc -&gt; pT-ERK_nuc</td>
<td>kf 3.8 x 10^{-3} /sec</td>
<td>8.6 x 10^{-3}</td>
<td>2.3 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re13</td>
<td>pY-ERK_nuc -&gt; np-ERK_nuc</td>
<td>kf 7.7 x 10^{-3} /sec</td>
<td>-4.5 x 10^{-3}</td>
<td>7.8 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re14</td>
<td>pT-ERK_nuc -&gt; np-ERK_nuc</td>
<td>kf 5.8 x 10^{-3} /sec</td>
<td>1.7 x 10^{-3}</td>
<td>6.9 x 10^{-3}</td>
<td></td>
</tr>
<tr>
<td>Re15</td>
<td>np-ERK_nuc -&gt; pMEK -&gt; pY-ERK_cyt</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re16</td>
<td>pY-ERK_cyt -&gt; pMEK -&gt; pTpY-ERK_cyt</td>
<td>kf 2.1 x 10^{4} /M/sec</td>
<td>1.6 x 10^{4}</td>
<td>1.3 x 10^{4}</td>
<td></td>
</tr>
<tr>
<td>Re17</td>
<td>pT-ERK_cyt -&gt; pMEK -&gt; pTpY-ERK_cyt</td>
<td>kf 2.0 x 10^{4} /M/sec</td>
<td>1.4 x 10^{4}</td>
<td>1.2 x 10^{4}</td>
<td></td>
</tr>
<tr>
<td>Re18</td>
<td>pMEK -&gt; pT-ERK -&gt; pMEK -&gt; pTpY-ERK_cyt</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re19</td>
<td>pMEK -&gt; np-ERK -&gt; pMEK -&gt; pTpY-ERK_cyt</td>
<td>kf 7.9 x 10^{-2} /sec</td>
<td>4.7 x 10^{-2}</td>
<td>3.9 x 10^{-2}</td>
<td></td>
</tr>
<tr>
<td>Re20</td>
<td>pMEK -&gt; pT-ERK -&gt; pMEK -&gt; pTpY-ERK_cyt</td>
<td>kf 5 x 10^{-2} /sec</td>
<td>3.0 x 10^{-2}</td>
<td>2.3 x 10^{-2}</td>
<td></td>
</tr>
</tbody>
</table>

The reaction number is indicated in Figure S8A and S8B. Bold character means enzyme. The symbols <--> and -> indicate a reversible reaction and an irreversible reaction, respectively. kf and kb are forward and reverse kinetic parameters, respectively.